scispace - formally typeset
J

Juan González-Lahoz

Researcher at Carlos III Health Institute

Publications -  279
Citations -  12635

Juan González-Lahoz is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Viral load & Hepatitis C virus. The author has an hindex of 54, co-authored 279 publications receiving 12489 citations. Previous affiliations of Juan González-Lahoz include Rafael Advanced Defense Systems.

Papers
More filters
Journal ArticleDOI

Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

Daniel D Murray, +1489 more
- 14 Oct 2015 - 
TL;DR: No associations with mortality were found with any circulating miRNAs studied and these results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major underlying diseases that contribute to mortality in participants treated for HIV-1 infection.
Journal ArticleDOI

Sociodemographic and psychological variables influencing adherence to antiretroviral therapy.

TL;DR: Overall, IVDUs and younger individuals tend to have a poorer compliance, as well as subjects with depression and lack of self-perceived social support, which should indirectly improve the effectiveness of antiretroviral therapy.
Journal ArticleDOI

Tuberculous Meningitis in Patients Infected with the Human Immunodeficiency Virus

TL;DR: Comparison with tuberculous meningitis in patients without HIV infection showed that the presentation, clinical manifestations, cerebrospinal fluid findings, and mortality were generally similar in the two groups.
Journal ArticleDOI

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients.

TL;DR: The proportion of hospital admissions caused by liver failure in HIV-infected patients has increased in the last 5 years, accounting for 16% of cases in 2000, and strategies to prevent infection by hepatitis viruses and specific treatment should be encouraged among HIV- infected persons.
Journal ArticleDOI

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter

TL;DR: Treatment with zidovudine benefits HIV-infected persons with CD4+ cell counts above 400 per cubic millimeter, and despite the use of doses larger than those now generally prescribed, zidvudine was well tolerated for up to three years by most of the authors' patients.